Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism
Not available.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/11971 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849773387119853568 |
|---|---|
| author | Catherine Duane Siobhan Glavey John Quinn Philip Murphy |
| author_facet | Catherine Duane Siobhan Glavey John Quinn Philip Murphy |
| author_sort | Catherine Duane |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-ec34b0107ad144fd9c58b30fb053acd2 |
| institution | DOAJ |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-ec34b0107ad144fd9c58b30fb053acd22025-08-20T03:02:04ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-03-01999110.3324/haematol.2025.287442Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolismCatherine Duane0Siobhan Glavey1John Quinn2Philip Murphy3Department of Haematology, Beaumont Hospital, Dublin, Ireland; RCSI University of Medicine and Health SciencesDepartment of Haematology, Beaumont Hospital, Dublin, Ireland; RCSI University of Medicine and Health SciencesDepartment of Haematology, Beaumont Hospital, Dublin, Ireland; RCSI University of Medicine and Health SciencesDepartment of Haematology, Beaumont Hospital, Dublin, Ireland; RCSI University of Medicine and Health Sciences Not available. https://haematologica.org/article/view/11971 |
| spellingShingle | Catherine Duane Siobhan Glavey John Quinn Philip Murphy Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism Haematologica |
| title | Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism |
| title_full | Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism |
| title_fullStr | Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism |
| title_full_unstemmed | Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism |
| title_short | Significant risk of venous thromboembolism associated with targeted anti-myeloma immunomodulatory drugs. Comment on: Targeted anti-cancer agents and risk of venous thromboembolism |
| title_sort | significant risk of venous thromboembolism associated with targeted anti myeloma immunomodulatory drugs comment on targeted anti cancer agents and risk of venous thromboembolism |
| url | https://haematologica.org/article/view/11971 |
| work_keys_str_mv | AT catherineduane significantriskofvenousthromboembolismassociatedwithtargetedantimyelomaimmunomodulatorydrugscommentontargetedanticanceragentsandriskofvenousthromboembolism AT siobhanglavey significantriskofvenousthromboembolismassociatedwithtargetedantimyelomaimmunomodulatorydrugscommentontargetedanticanceragentsandriskofvenousthromboembolism AT johnquinn significantriskofvenousthromboembolismassociatedwithtargetedantimyelomaimmunomodulatorydrugscommentontargetedanticanceragentsandriskofvenousthromboembolism AT philipmurphy significantriskofvenousthromboembolismassociatedwithtargetedantimyelomaimmunomodulatorydrugscommentontargetedanticanceragentsandriskofvenousthromboembolism |